1. US Food & Drug Administration. FDA approves treatment for Ebola virus [media release]. 21 Dec 2020. https://www.fda.gov/.
2. Ridgeback Biotherapeutics. EBANGA (ansuvimab-zykl): US prescribing information. 2021. https://dailymed.nlm.nih.gov/. Accessed 28 Jan 2021.
3. Corti D, Misasi J, Mulangu S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351(6279):1339–42.
4. Ridgeback Biotherapeutics. Ridgeback Biotherapeutics LP announces the approval of Ebanga™ for Ebola [media release]. 22 Dec 2020. https://ridgebackbio.com/.
5. Ridgeback Biotherapeutics. Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases [media release]. 13 Dec 2018. https://ridgebackbio.com/.